A new paper about a Gilead drug to combat coronavirus has some analysts skittish about success
As anticipation mounts over the prospects for an experimental Gilead Sciences (GILD) drug to combat the novel coronavirus, two Wall Street analysts suggested it remains uncertain whether the antiviral therapy will be successful after assessing a new paper that examined a dozen U.S. patients.
The paper, published on a preprint server without peer review, described the epidemiology, clinical course, and viral characteristics of the first 12 U.S. patients with Covid-19, only three of whom were treated with remdesivir, which was developed to treat the Ebola virus but shelved after proving less effective than other drugs during testing. The analysis was conducted by the Centers for Disease Control and Prevention Covid-19 response team.
